PDCD1 and neoplasm: However, exploratory analysis of the Keynote 042 trial suggests that among patients with tumours expressing PD-L1 in ≥ 50% of cells, only those whose TMB was higher than the median exhibited any therapeutic benefit with PD-1/PD-L1 inhibitors as compared to chemotherapy [70].